Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of sotatercept in combined post- and pre-capillary pulmonary hypertension due to HFpEF
MOH_2021-11-09_010378Phase 2Not yet recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sotatercept in pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by Acceleron Pharma Inc. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on MOH_2021-11-09_010378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-09_010378.